AKTIS ONCOLOGY INC (AKTS) Stock Fundamental Analysis

NASDAQ:AKTS • US01021M1045

20 USD
+0.57 (+2.93%)
At close: Feb 24, 2026
20 USD
0 (0%)
After Hours: 2/24/2026, 8:08:20 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall AKTS gets a fundamental rating of 4 out of 10. We evaluated AKTS against 521 industry peers in the Biotechnology industry. AKTS has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, AKTS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year AKTS has reported negative net income.
  • In the past year AKTS has reported a negative cash flow from operations.
  • AKTS had negative earnings in each of the past 5 years.
  • AKTS had negative operating cash flow in 4 of the past 5 years.
AKTS Yearly Net Income VS EBIT VS OCF VS FCFAKTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • With a decent Return On Assets value of -15.76%, AKTS is doing good in the industry, outperforming 79.27% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -21.88%, AKTS belongs to the top of the industry, outperforming 82.53% of the companies in the same industry.
Industry RankSector Rank
ROA -15.76%
ROE -21.88%
ROIC N/A
ROA(3y)-26.52%
ROA(5y)-33.1%
ROE(3y)-30.21%
ROE(5y)-43.07%
ROIC(3y)N/A
ROIC(5y)N/A
AKTS Yearly ROA, ROE, ROICAKTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AKTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKTS Yearly Profit, Operating, Gross MarginsAKTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • AKTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AKTS has about the same amount of shares outstanding.
  • AKTS has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for AKTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AKTS Yearly Shares OutstandingAKTS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
AKTS Yearly Total Debt VS Total AssetsAKTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • AKTS has an Altman-Z score of 7.43. This indicates that AKTS is financially healthy and has little risk of bankruptcy at the moment.
  • AKTS's Altman-Z score of 7.43 is fine compared to the rest of the industry. AKTS outperforms 77.54% of its industry peers.
  • There is no outstanding debt for AKTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.43
ROIC/WACCN/A
WACC8.7%
AKTS Yearly LT Debt VS Equity VS FCFAKTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 9.27 indicates that AKTS has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 9.27, AKTS is doing good in the industry, outperforming 79.46% of the companies in the same industry.
  • A Quick Ratio of 9.27 indicates that AKTS has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 9.27, AKTS is doing good in the industry, outperforming 79.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.27
Quick Ratio 9.27
AKTS Yearly Current Assets VS Current LiabilitesAKTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for AKTS have decreased strongly by -53.55% in the last year.
  • Measured over the past years, AKTS shows a small growth in Revenue. The Revenue has been growing by 0.64% on average per year.
EPS 1Y (TTM)-53.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.21%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-39.21%
Revenue growth 5Y0.64%
Sales Q2Q%-38.39%

3.2 Future

  • Based on estimates for the next years, AKTS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.01% on average per year.
  • AKTS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.27% yearly.
EPS Next Y42.58%
EPS Next 2Y20.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.7%
Revenue Next 2Y34.27%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AKTS Yearly Revenue VS EstimatesAKTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
AKTS Yearly EPS VS EstimatesAKTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AKTS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKTS Price Earnings VS Forward Price EarningsAKTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKTS Per share dataAKTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • AKTS's earnings are expected to grow with 20.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.01%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AKTS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AKTIS ONCOLOGY INC

NASDAQ:AKTS (2/24/2026, 8:08:20 PM)

After market: 20 0 (0%)

20

+0.57 (+2.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)02-11
Inst OwnersN/A
Inst Owner Change-73.62%
Ins OwnersN/A
Ins Owner Change0%
Market Cap1.01B
Revenue(TTM)1.49M
Net Income(TTM)-43.98M
Analysts45.71
Price TargetN/A
Short Float %0.44%
Short Ratio0.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-575%
EPS NQ rev (3m)-575%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-70.37%
Revenue NQ rev (3m)-70.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 681.24
P/FCF N/A
P/OCF N/A
P/B 5.04
P/tB 5.04
EV/EBITDA N/A
EPS(TTM)-0.87
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0.03
BVpS3.97
TBVpS3.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.76%
ROE -21.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.52%
ROA(5y)-33.1%
ROE(3y)-30.21%
ROE(5y)-43.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 369.11%
Cap/Sales 515.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.27
Quick Ratio 9.27
Altman-Z 7.43
F-Score3
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)345.4%
Cap/Depr(5y)325.46%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.21%
EPS Next Y42.58%
EPS Next 2Y20.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-39.21%
Revenue growth 5Y0.64%
Sales Q2Q%-38.39%
Revenue Next Year29.7%
Revenue Next 2Y34.27%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-49.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.38%
OCF growth 3YN/A
OCF growth 5YN/A

AKTIS ONCOLOGY INC / AKTS FAQ

What is the ChartMill fundamental rating of AKTIS ONCOLOGY INC (AKTS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to AKTS.


What is the valuation status for AKTS stock?

ChartMill assigns a valuation rating of 1 / 10 to AKTIS ONCOLOGY INC (AKTS). This can be considered as Overvalued.


How profitable is AKTIS ONCOLOGY INC (AKTS) stock?

AKTIS ONCOLOGY INC (AKTS) has a profitability rating of 1 / 10.


What is the financial health of AKTIS ONCOLOGY INC (AKTS) stock?

The financial health rating of AKTIS ONCOLOGY INC (AKTS) is 8 / 10.